Loading stock data…
TWST
$128.06+3.34 (+2.68%)
Market ClosedLast close Sep 8
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Twist Bioscience Corporation in the Healthcare sector is trading at $128.06 with a market capitalization of $5.3B. Wall Street consensus targets $108.60 (10 analysts), implying a -15.2% move over the next 12 months. The stock is currently 18% below its 52-week high of $155.44, remaining 96.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -15.2% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $118.38M↑ | $110.72M↑ | $103.70M↑ | $99.01M↑ | $96.06M |
| Gross Profit | $62.45M↑ | $57.12M↑ | $53.97M↑ | $50.84M↓ | $51.30M |
| Operating Income | -$36.28M↑ | -$38.66M↓ | -$33.10M↓ | -$29.93M↑ | -$30.12M |
| Net Income | -$35.05M↑ | -$44.02M↓ | -$30.51M↓ | -$27.14M↓ | $20.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.86%
Volume
Today's trading volume
1.81M
Recent News
Twist Bioscience (TWST) Rallied as AI and Pharma Drive DNA Demand
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
What Is Cathie Wood Buying Now? Nvidia, SpaceX And Crypto Stocks Led ARK’s August Trades – While Cutting These Growth Stocks
Nvidia was ARK’s biggest August purchase, with roughly 548,000 shares added during the month.
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 3.1% a
‘Pharma Bro’ Martin Shkreli Slams Anthropic’s Claude Drug-Discovery Claims: ‘This Is Not Impressive Work’
Claude-designed proteins successfully bound to 14 of 15 targets in independent testing by Adaptyv Bio and Twist Bioscience.
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.